Quenet Torrent Institute: a new therapeutic strategy in oncology

It is an integrated approach that combines maximal cytoreductive surgery, regional therapies such as HIPEC and PIPAC, personalised medicine based on the molecular profile of the tumour, and weekly multidisciplinary decision-making. The plan is decided case by case according to each patient's clinical situation.

It is oncological surgery that aims to remove all visible tumour disease, including lesions that were previously considered unresectable. It achieves complete resection (R0) rates above 85% in complex sarcomas.

Combining cytoreductive surgery with HIPEC makes it possible to apply chemotherapy directly into the peritoneal cavity at high concentration and temperature. In peritoneal carcinomatosis, this strategy can reach median survivals of 40 to 60 months, compared with 12-18 months with systemic chemotherapy alone.

It means adapting treatment to the specific molecular characteristics of each patient's tumour, by analysing markers such as BRCA, HER2 or RAS. This approach improves treatment efficacy and reduces unnecessary exposure to drugs that work poorly for that tumour profile.

It is a weekly meeting in which surgeons, oncologists, radiologists and pathologists review each case together. This way the treatment decision is made by several specialties together and not by a single doctor.

Robotic surgery, intraoperative imaging and augmented reality make it possible to plan and carry out resections with greater precision. These tools reduce bleeding, improve the identification of oncological margins and lower postoperative complications.

PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) delivers chemotherapy as a pressurised aerosol inside the abdominal cavity by laparoscopy. It is used when complete cytoreduction is not immediately possible, as palliative treatment or as a bridge to later surgery with HIPEC.

Patients with peritoneal carcinomatosis of colorectal, ovarian, gastric or appendiceal origin; with complex sarcomas; with liver metastases; and patients who have been told at other centres that their disease is unresectable. Each case requires an individual multidisciplinary assessment.

With this strategy, our team achieves complete cytoreduction in more than 80% of advanced ovarian cancer cases. Complete cytoreduction is the most important prognostic factor in this disease, and achieving it significantly improves long-term survival.

Yes. Our team assesses cases from anywhere in Spain and abroad. After reviewing the clinical records and imaging, we provide a detailed assessment of the available treatment options and the indication for each one.